TAKEDA Pharmaceuticals Australia has announced the Pharmaceutical Benefits Scheme (PBS) listing of Adcetris (brentuximab vedotin), therapy for patients with relapsed or refractory Hodgkin lymphoma (HL).
In Australia, more than 600 people are diagnosed with HL per year and require front-line treatment, while up to 30% of these relapse and require further treatment, Takeda said.
The above article was sent to subscribers in Pharmacy Daily's issue from 28 Mar 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Mar 17